Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results

#3219

Introduction: Increasing LAN dose frequency may extend progression-free survival (PFS).

Aim(s): Efficacy, safety and QoL with increasing LAN dose frequency from every (q) 28 days (standard) to q14 days in patients with a progressive pancreatic NET (panNET) or midgut NET were assessed.

Materials and methods: A prospective, single-arm, open-label, European phase 2 study in patients with a metastatic or locally advanced, unresectable, G1/2 panNET or midgut NET and centrally assessed progression in the last 2 years while on standard LAN for ≥24 weeks (NCT02651987). LAN 120 mg q14 days was administered for 48 (panNET) or 96 (midgut) weeks (or until progressive disease or death [events], or unacceptable toxicity), or longer if <25 events/cohort occurred.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Pavel M

Authors: Pavel M, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Lanreotide, neuroendocrine tumor, pancreatic, midgut, quality of life,